Last update 23 Nov 2024

HRS-4357

Overview

Basic Info

Drug Type
Small molecule drug, Therapeutic radiopharmaceuticals
Synonyms
HRS 4357, HRS-4357, HRS4357
Target
PSMA
Mechanism
PSMA inhibitors(Prostate-specific membrane antigen inhibitors)
Therapeutic Areas
NeoplasmsUrogenital Diseases
Active Indication
Advanced Prostate CarcinomaPSMA-Positive Prostatic CancerPSMA-Positive Castration-Resistant Prostatic Cancer
Inactive Indication-
Originator Organization
Tianjin Hengrui Pharmaceutical Co., Ltd
Active Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.Tianjin Hengrui Pharmaceutical Co., Ltd
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with HRS-4357
CTR20232716 / RecruitingPhase 1/2
HRS-4357用于PSMA阳性晚期前列腺癌患者治疗的药代动力学及辐射剂量学、安全性及初步有效性评价的I/II期临床研究
[Translation] A Phase I/II clinical study of HRS-4357 for the treatment of patients with PSMA-positive advanced prostate cancer: pharmacokinetics, radiation dosimetry, safety, and preliminary efficacy evaluation
NCT06006104 / Not yet recruitingPhase 1/2
A Phase I/II Clinical Study to Evaluate the Pharmacokinetics, Radiation Dosimetry, Safety and Preliminary Efficacy of HRS-4357 in Patients With PSMA Positive Advanced Prostate Cancer
100 Clinical Results associated with HRS-4357
Login to view more data
100 Translational Medicine associated with HRS-4357
Login to view more data
100 Patents (Medical) associated with HRS-4357
Login to view more data
100 Deals associated with HRS-4357
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Prostate CarcinomaPhase 2-
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.
30 Sep 2023
PSMA-Positive Prostatic CancerPhase 2-
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Jiangsu Hengrui Pharmaceuticals Co., Ltd.
30 Sep 2023
PSMA-Positive Castration-Resistant Prostatic CancerIND Approval
CN
Tianjin Hengrui Pharmaceutical Co., Ltd
30 Jun 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free